Research Journal of Pharmaceutical Dosage Forms and Technology

  • Year: 2024
  • Volume: 16
  • Issue: 3

Beyond solubility: An uncharted area of bioavailability enhancement research for better therapeutics

  • Author:
  • Riyaz Khan, Wajid Ahmad, Razia Pathan, Vishal Jain, Dipali Rajput
  • Total Page Count: 8
  • Published Online: Jul 10, 2025
  • Page Number: 221 to 228

Department of Pharmaceutics, Institute and Research College of Pharmacy, Turkey

Abstract

Various systems are utilized to build the bioavailability of pharmacoactive particles in light of the fact that their low water dissolvability restricts their pharmacological potential however the solvency boundary can’t be compromised. Low solvency chemically dynamic particles demonstrate a higher opportunity of medication improvement and development disappointment. Perhaps of the greatest test in the field of drug details is working on the solvency and bioavailability of prescriptions. The Arrangement of Biopharmaceutics states that medications in classes II and IV (APIs) have unfortunate solvency, lower bioavailability, and less disintegration. The Complexation of dynamic atoms, the utilization of co solvents, precious stone designing procedures, drug nanocrystals, emulsion development, micelles, miniature emulsions, nanomorph innovation, molecule size decrease advancements, drug salts, prodrug, the strong state rotation strategy, delicate gel innovation and strong scattering techniques are only a couple of the advances that are examined in this article to work on the dissolvability of inadequately water-dissolvable medications. This survey centers around various other state of the art methods for further developing solvency and bioavailability, including drug forms, cyclodextrins, strong lipid nanoparticles, micronization, strong scatterings, nanosizing, and colloidal medication conveyance frameworks. It does this by refering to various appropriate exploration reports.

Keywords

Bioavailability, BCS arrangement, Strong scattering, Self-emulsifying drug conveyance frameworks